RU2015144872A - Pyrimidyl di (dispiroalkane) s with antiviral activity - Google Patents

Pyrimidyl di (dispiroalkane) s with antiviral activity Download PDF

Info

Publication number
RU2015144872A
RU2015144872A RU2015144872A RU2015144872A RU2015144872A RU 2015144872 A RU2015144872 A RU 2015144872A RU 2015144872 A RU2015144872 A RU 2015144872A RU 2015144872 A RU2015144872 A RU 2015144872A RU 2015144872 A RU2015144872 A RU 2015144872A
Authority
RU
Russia
Prior art keywords
diyl
alk
prevention
treatment
pyrimidine
Prior art date
Application number
RU2015144872A
Other languages
Russian (ru)
Other versions
RU2633699C2 (en
Inventor
Вадим Альбертович Макаров
Владимир Георгиевич Нестеренко
Роман Николаевич Болгарин
Елена Александровна Новоселова
Original Assignee
Общество С Ограниченной Ответственностью "Ниармедик Плюс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Ниармедик Плюс" filed Critical Общество С Ограниченной Ответственностью "Ниармедик Плюс"
Priority to RU2015144872A priority Critical patent/RU2633699C2/en
Priority to PCT/RU2016/050040 priority patent/WO2017069661A1/en
Publication of RU2015144872A publication Critical patent/RU2015144872A/en
Application granted granted Critical
Publication of RU2633699C2 publication Critical patent/RU2633699C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Claims (25)

1. Соединение соответствующее общей структурной формуле I.1. The compound corresponding to the General structural formula I.
Figure 00000001
Figure 00000001
 где X = СН2, Y = СН2СН2 или X = СН2СН2, Y = СН2;where X = CH 2 , Y = CH 2 CH 2 or X = CH 2 CH 2 , Y = CH 2 ; А означает пиримидин-4,6-диил или пиримидин-2,4-диил, который может иметь в качестве заместителей Н, NO2, СНО, ОН, OAlk, атом галогена, NH(Alk), N(Alk)2 группу; где Alk означает линейный или разветвленный заместитель имеющий от 1 до 4 атомов углерода;A means pyrimidine-4,6-diyl or pyrimidine-2,4-diyl, which may have substituents H, NO 2 , CHO, OH, OAlk, a halogen atom, NH (Alk), N (Alk) 2 group; where Alk means a linear or branched substituent having from 1 to 4 carbon atoms; Hal означает атом галогена, или его фармацевтически приемлемые соли.Hal means a halogen atom, or its pharmaceutically acceptable salts. 2. Соединение по п. 1, где X = Y = СН2 2. The compound according to claim 1, where X = Y = CH 2 А означает пиримидин-4,6-диил или пиримидин-2,4-диил, который имеет в качестве заместителя атом Cl, Br, СН3, ОН;And means pyrimidine-4,6-diyl or pyrimidine-2,4-diyl, which has a substituent atom Cl, Br, CH 3 , HE; Hal означает атом галогена, хлор или бром;Hal means a halogen atom, chlorine or bromine; за исключением соединений 3,3'-(5-нитропиримидин-4,6-диил)бис-3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан тетрахлорида и 3,3'-(2-метил-5-нитропиримидин-4,6-диил)бис-3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан тетрахлорида.with the exception of compounds 3,3 '- (5-nitropyrimidin-4,6-diyl) bis-3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecane tetrachloride and 3.3' - (2-methyl- 5-nitropyrimidin-4,6-diyl) bis-3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecane tetrachloride. 3. Соединение согласно формуле (I), где X = СН2СН2, Y = СН2; А = пиримидин-4,6-диил, который может иметь в качестве заместителей Н, NO2, Alk группу; Hal = хлор или бром и Alk = метил.3. The compound according to formula (I), where X = CH 2 CH 2 , Y = CH 2 ; A = pyrimidin-4,6-diyl, which may have H, NO 2 , Alk group as substituents; Hal = chlorine or bromine and Alk = methyl. 4. Соединение согласно формуле (I), где X = СН2, Y = СН2СН2, А = пиримидин-4,6-диил, который может иметь в качестве заместителей Н, NO2, Alk группу; Hal = хлор или бром и Alk = метил.4. The compound according to formula (I), where X = CH 2 , Y = CH 2 CH 2 , A = pyrimidin-4,6-diyl, which may have H, NO 2 , Alk group as substituents; Hal = chlorine or bromine and Alk = methyl. 5. Применение соединений по формуле (I) по п. 1 или их фармацевтически приемлемых солей5. The use of compounds of formula (I) according to claim 1 or their pharmaceutically acceptable salts
Figure 00000002
Figure 00000002
 гдеWhere X = Y = СН2 или X = СН2, Y = СН2СН2 или X = СН2СН2, Y = СН2;X = Y = CH 2 or X = CH 2 , Y = CH 2 CH 2 or X = CH 2 CH 2 , Y = CH 2 ; А = пиримидин-4,6-диил или пиримидин-2,4-диил, который может иметь в качестве заместителей Н, NO2, СНО, ОН, OAlk, Cl, NHAlk, NAlk2 группу;A = pyrimidine-4,6-diyl or pyrimidine-2,4-diyl, which may have H, NO 2 , CHO, OH, OAlk, Cl, NHAlk, NAlk 2 as substituents; Hal = хлор или бром;Hal = chlorine or bromine; Alk = линейный или разветвленный заместитель имеющий от 1 до 4 атомов углерода обладающих противовирусной активностью для профилактики или лечения заболеваний, вызываемых вирусной инфекцией;Alk = a linear or branched substituent having from 1 to 4 carbon atoms having antiviral activity for the prevention or treatment of diseases caused by viral infection; за исключением соединений 3,3'-(5-нитропиримидин-4,6-диил)бис-3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан тетрахлорида и 3,3'-(2-метил-5-нитропиримидин-4,6-диил)бис-3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан тетрахлорида.with the exception of compounds 3,3 '- (5-nitropyrimidin-4,6-diyl) bis-3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecane tetrachloride and 3.3' - (2-methyl- 5-nitropyrimidin-4,6-diyl) bis-3,12-diaza-6,9-diazoniadispiro [5.2.5.2] hexadecane tetrachloride. 6. Применение соединений по п. 1-4 для профилактики и/или лечения папиллома вирусной инфекции у человека и животных.6. The use of compounds according to claim 1-4 for the prevention and / or treatment of papilloma virus infection in humans and animals. 7. Применение соединений по п. 1-4 для профилактики и/или лечения вирусной инфекции у человека, вызванной вирусом иммунодефицита.7. The use of compounds according to claim 1-4 for the prevention and / or treatment of viral infection in humans caused by the immunodeficiency virus. 8. Применение соединений по п. 1-4 для профилактики и/или лечения вирусной инфекции у человека, вызванной цитомегаловирусом.8. The use of compounds according to p. 1-4 for the prevention and / or treatment of viral infections in humans caused by cytomegalovirus. 9. Применение соединений по п. 1-4 для профилактики и/или лечения вирусной инфекции у человека, вызванной вирусом гепатита В или С.9. The use of compounds according to p. 1-4 for the prevention and / or treatment of viral infections in humans caused by hepatitis B or C. 10. Применение соединений по п. 2 для профилактики и/или лечения вирусной инфекции у человека и животных.10. The use of compounds according to claim 2 for the prevention and / or treatment of viral infections in humans and animals. 11. Применение соединений по п. 5 для профилактики и/или лечения папиллома вирусной инфекции у человека и животных.11. The use of compounds according to claim 5 for the prevention and / or treatment of papilloma virus infection in humans and animals.
RU2015144872A 2015-10-20 2015-10-20 Pyrimidyl-di(diazadispiroalkane)s with antiviral activity RU2633699C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2015144872A RU2633699C2 (en) 2015-10-20 2015-10-20 Pyrimidyl-di(diazadispiroalkane)s with antiviral activity
PCT/RU2016/050040 WO2017069661A1 (en) 2015-10-20 2016-09-21 Pyrimidyl-di(diazaspiro-alkanes) with antiviral activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015144872A RU2633699C2 (en) 2015-10-20 2015-10-20 Pyrimidyl-di(diazadispiroalkane)s with antiviral activity

Publications (2)

Publication Number Publication Date
RU2015144872A true RU2015144872A (en) 2017-05-03
RU2633699C2 RU2633699C2 (en) 2017-10-17

Family

ID=57517957

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015144872A RU2633699C2 (en) 2015-10-20 2015-10-20 Pyrimidyl-di(diazadispiroalkane)s with antiviral activity

Country Status (2)

Country Link
RU (1) RU2633699C2 (en)
WO (1) WO2017069661A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH502760A (en) * 1967-01-04 1971-02-15 Basf Ag Preparations for the inhibition of plant growth and for changing the plant habit
WO2009154201A1 (en) * 2008-06-18 2009-12-23 国立大学法人京都大学 Cell adhesion promoting agent and method of promoting cell adhesion
JPWO2013168807A1 (en) * 2012-05-11 2016-01-07 国立大学法人京都大学 Additives and therapeutic compositions for transplanted cell suspensions
RU2573977C9 (en) * 2014-04-30 2016-08-27 Общество С Ограниченной Ответственностью "Ниармедик Плюс" 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application

Also Published As

Publication number Publication date
WO2017069661A1 (en) 2017-04-27
RU2633699C2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
HRP20211224T1 (en) Pyrimidine derivatives for the treatment of viral infections
JP2016530259A5 (en)
MX2018009944A (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazo l-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahyd ro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid.
HRP20210027T1 (en) Cyclic dinucleotide compounds
JP2014521688A5 (en)
JP2017537949A5 (en)
JP2019509276A5 (en)
RU2020110780A (en) FGFR INHIBITOR AND ITS MEDICAL APPLICATIONS
MA38323A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2017530959A5 (en)
RU2017107026A (en) IDO INHIBITORS
JP2021500394A5 (en)
RU2016134751A (en) COMPOUNDS
JP2012522729A5 (en)
EA201690978A1 (en) PIRROLO [1.2-f] [1.2.4] TRIAZINES USED FOR THE TREATMENT OF RESPIRATORY-SYNCTIAL VIRAL INFECTIONS
JP2013544860A5 (en)
ATE512973T1 (en) NUCLEOSIDE ARYLPHOSPHORAMIDATES AND THEIR USE AS ANTIVIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS
EA202190602A3 (en) 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY RNA VIRUS
JP2016503797A5 (en)
AR117189A1 (en) DERIVATIVES OF 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
JP2017533263A5 (en)
JP2014501766A5 (en)
JP2019532092A5 (en)
EA201790146A1 (en) THIENO [3,2-d] PYRIMIDIN, FURO [3,2-d] PYRIMIDINE AND PYRROLO [3,2-d] PYRIMIDINES, SUITABLE FOR THE TREATMENT OF INFECTIONS, CAUSED BY A RESPIRATOR-SYNCIALIAL VIRUS
JP2017532294A5 (en)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181021